News | February 14, 2025
Lupin Q3 FY25 profit up 40% at Rs. 855 Cr
Revenue up 11% to Rs 5,768 crore as compared to Rs 5,197 crore
Revenue up 11% to Rs 5,768 crore as compared to Rs 5,197 crore
The company said it voluntarily paused production at the Gagillapur plant in September 2024 for risk assessment on account of the USFDA observations
According to IQVIATM sales data for the 12-month period ending November 2024, the Vitamin K1 Injectable Emulsion USP, 10 mg/mL market achieved annual sales of approximately $19.7 million
Hyper-automated AI is a unified framework combining AI, ML, RPA, and NLQ to streamline data extraction, quality management, transformation, and actionable insights - all on a single platform
The transaction is part of a broader agreement with Bureau Veritas covering its worldwide food laboratory testing activities
Increases speed to market for drug developers working on nucleic acid therapeutics
Fiscal 2024 total sales for the joint venture were approximately $190 million
Immedica to commence a cash tender offer to acquire all issued and outstanding shares of Marinus for an enterprise value of approximately US$ 151 million
According to IQVIATM sales data for the 12-month period ending October 2024, the Vimpat Oral Solution, 10 mg/mL market achieved annual sales of approximately $57.0 million
New research labs and process development services to enable next generation therapeutics
Subscribe To Our Newsletter & Stay Updated
